Dr. James D. Osborn, MD

Dr. Osborn practices at Castleview Hospital in Price, Utah, part of Lifepoint Health.

Dr. Osborn's NPI, 1235364902, was assigned on May 23, 2009. Dr. Osborn graduated from University of Toledo College of Medicine in 2009. Dr. Osborn holds Utah license 7770257-1205.

Dr. Osborn's primary practice is Castleview Hospital, at 300 North Hospital Drive, Price, UT 84501 in Carbon County. The practice phone is (435) 637-4800.

Dr. Osborn's primary practice is Castleview Hospital in Price, Utah, part of Lifepoint Health. Dr. Osborn is also affiliated with University of Utah Hospital. The medical group on file is Intermountain Health. Dmand AI also links Dr. Osborn to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Osborn practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Osborn's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Osborn is licensed in Utah.

CMS data shows 73 Medicare services from Dr. Osborn across 3 procedure codes in 2024, for 31 Medicare patients. Medicare paid $4,978 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 31 Medicare patients who saw Dr. Osborn in 2024. The largest group is 65 to 74, with 19 patients. 74% of them have high blood pressure, and 58% have high cholesterol. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Osborn's median patient age at 71, with 37% women.

In 2024, Dr. Osborn wrote 16 Medicare Part D claims. They cover 2 drugs, with $681 in total drug cost. In 2020, CMS named 28 claims across 2 drugs.

Dr. Osborn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Osborn as offering telehealth.

Dmand AI links 12 papers to Dr. Osborn in 2019. 2019 was the busiest year, with 2. The most frequent topics are Hematopoietic Stem Cell Transplantation. Dr. Osborn has published most often in Opt Express. Dr. Osborn's most frequent co-authors are Margaret K. Baron, MD, Michael Wayne Boyer, MD and Gerhard Carl Hildebrandt, MD.

CMS Open Payments shows 5 general payments to Dr. Osborn from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 69% of the total. Legend Biotech USA Inc. paid the most, $79.

Dr. Osborn graduated from University of Toledo College of Medicine in 2009.